Empagliflozin 25 mg Tablets (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202102263 · Approved 2021.03.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to help control blood sugar in adults with type 2 diabetes. It can be administered alone, and if blood sugar control is inadequate, it may be used in combination with metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin. Particularly, patients with type 2 diabetes confirmed to have cardiovascular disease need to be cautious about the occurrence of cardiovascular events. This medication is used to improve blood sugar control and assist in the management of the patient's health.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If additional glycemic control is needed and 10 mg of this medicine is well tolerated, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you forget to take this medicine, take it as soon as you remember. Do not take double the dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in older adults aged 85 years and older due to limited clinical experience (see Precautions for Use, section 4, General Precautions).
This medication should not be used in patients with an allergy to the active ingredient or any components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. It should not be used in patients with severely impaired kidney function or end-stage kidney disease or during dialysis. This medication contains lactose and should not be taken by patients with genetic disorders such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption. In patients with mild renal impairment, this medication should be used with caution, and dosage adjustments or discontinuation may be necessary. In patients with mild to moderate heart failure, it should be used cautiously, and it is not recommended for those with severe heart failure. When used together with blood glucose-lowering agents such as insulin or sulfonylureas, there is a risk of hypoglycemia, so the doses of these medications may need to be reduced. During the use of this medication, there may be side effects such as hypoglycemia, urinary tract infections, genital infections, and increased urination, so caution is advised. Especially, serious metabolic abnormalities such as ketoacidosis may occur. Therefore, if symptoms such as vomiting, abdominal pain, or difficulty breathing appear, immediate consultation with a healthcare professional is necessary. In elderly patients or those at risk of fluid volume depletion or hypotension, careful administration is required, and fluid status should be checked frequently. This medication may cause serious urinary infections such as urosepsis or pyelonephritis, so rapid treatment is required if infection symptoms occur. Pregnant or breastfeeding women are advised not to use this medication and should discontinue use upon confirmation of pregnancy. The safety and efficacy in children under the age of 18 have not been established. There have been no reported special toxicities in case of overdose, but appropriate treatment should be administered according to clinical condition. During the use of this medication, it should be kept out of the reach of children and care should be taken not to transfer to other containers. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia, especially when taken together with insulin or sulfonylureas. Diabetic patients should seek medical attention immediately if they experience pain or swelling in the perineum or other areas during regular foot care.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. This will help maintain the efficacy of the medication safely.
Light yellow biconvex oval film-coated tablet
10 tablets/box [(10 tablets/PTP x 1)], 30 tablets/box [(10 tablets/PTP x 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.